D-Foot2019: Digital Foot Check by Using the D-Foot, a New Software

Sponsor
Sahlgrenska University Hospital, Sweden (Other)
Overall Status
Completed
CT.gov ID
NCT04054804
Collaborator
(none)
100
1
3.5
28.7

Study Details

Study Description

Brief Summary

Patients with diabetes should be thoroughly examined before they are provided with insoles and shoes. In the study the feet are examined with the help of a new software, the D-Foot. D-Foot includes questions and surveys.

The aim of the of the study is evaluate how the patients experience the visit at the department of Prosthetics & Orthotics based on the digital foot check.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: D-Foot

Detailed Description

Patients with diabetes should be thoroughly examined before they are provided with insoles and shoes. The purpose of the foot examination is to determine whether the patient is at risk of developing diabetic foot ulcers (DFU). Risk factors are: neuropathy, peripheral angiopathy, foot deformities, skin pathologies, earlier history of DFU/amputation. With effective control and examination of the feet, foot complications, such as DFU, can be prevented. In the study the feet are examined with the help of a new software, the D-Foot. D-Foot includes questions and surveys.

The aim of the of the study is evaluate how the patients experience the visit at the department of Prosthetics & Orthotics based on the digital foot check.

Study Design

Study Type:
Observational
Actual Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Digital Foot Check by Using the D-Foot, a New Software
Actual Study Start Date :
Sep 16, 2019
Actual Primary Completion Date :
Dec 31, 2019
Actual Study Completion Date :
Dec 31, 2019

Outcome Measures

Primary Outcome Measures

  1. The questionnaire Orthotic and Prosthetic Users Survey (OPUS) will be used. [2019-2020]

    Participants satisfaction with devices and services at the Department of Prosthetics and Orthotics will be evaluated.

Secondary Outcome Measures

  1. Presence of neuropathy (number) [2019-2020]

    From the software, D-Foot, the number of participants having neuropathy will be reported.

  2. Presence of neuropathy (percentage) [2019-2020]

    From the software, D-Foot, the percentage of participants having neuropathy will be reported

  3. Presence of peripheral angiopathy (number ) [2019-2020]

    From the software, D-Foot, the number of participants having peripheral angiopathy will be reported.

  4. Presence of peripheral angiopathy (percentage ) [2019-2020]

    From the software, D-Foot, the percentage of participants having peripheral angiopathy will be reported.

  5. Presence of calluses (number) [2019-2020]

    From the software, D-Foot, the number of participants having calluses will be reported.

  6. Presence of calluses (percentage) [2019-2020]

    From the software, D-Foot, the percentage of participants having calluses will be reported,

  7. Presence of foot deformities (number) [2019-2020]

    From the software, D-Foot, the number of participants having foot deformities eg. hammertoes, hallux valgus will be reported.

  8. Presence of foot deformities (percentage) [2019-2020]

    From the software, D-Foot, the percentage of participants having foot deformities eg. hammertoes, hallux valgus will be reported.

  9. Presence of foot ulcers (number) [2019-2020]

    From the software, D-Foot, the number of participants having foot ulcers will be reported.

  10. Presence of foot ulcers (percentage) [2019-2020]

    From the software, D-Foot, the percentage of participants having foot ulcers will be reported.

  11. Presence of previous foot ulcers (number) [2019-2020]

    From the software, D-Foot, the number of participants with previous foot ulcers will be reported.

  12. Presence of previous foot ulcers (percentage) [2019-2020]

    From the software, D-Foot, the percentage of participants with previous foot ulcers will be reported.

  13. Presence of previous amputation in the lower extremities (number) [2019-2020]

    From the software, D-Foot, the number of participants with previous amputation in the lower extremities will be reported.

  14. Presence of previous amputation in the lower extremities (percentage) [2019-2020]

    From the software, D-Foot, the percentage of participants with previous amputation in the lower extremities will be reported.

  15. System Usability Scale (SUS). The score range from 0-100 and a SUS score above a 68 would be considered above average and anything below 68 is below average. [2019-2020]

    The SUS provides a reliable tool for measuring the usability. It consists of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. SUS allows you to evaluate a wide variety of products and services, including hardware, software, mobile devices, websites and applications. In this setting the aim is to evaluate how certified prosthetists & orthotists experience the use the web program D-Foot when they examine the patients feet?

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria for patients:
  • To be diagnosed diabetes

  • Age ≥ 18 years

  • To understand the Swedish language.

Inclusion Criteria for certified prosthetist & orthotists

  • To work at the department

  • To be assigned to work with patients with diabetes at risk of developing foot ulcers.

  • Have completed the introduction course D-foot

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Prostetics & Orthotics Gothenburg Region Västragötaland Sweden 41285

Sponsors and Collaborators

  • Sahlgrenska University Hospital, Sweden

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ulla Hellstrand Tang, Principal Investigator, Sahlgrenska University Hospital, Sweden
ClinicalTrials.gov Identifier:
NCT04054804
Other Study ID Numbers:
  • D-Foot 2019
First Posted:
Aug 13, 2019
Last Update Posted:
Oct 28, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ulla Hellstrand Tang, Principal Investigator, Sahlgrenska University Hospital, Sweden
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 28, 2020